SARC-F: a Symptom Score to Predict Persons with Sarcopenia at Risk for Poor Functional Outcomes
Overview
Affiliations
Background: A brief, inexpensive screening test for sarcopenia would be helpful for clinicians and their patients. To screen for persons with sarcopenia, we developed a simple five-item questionnaire (SARC-F) based on cardinal features or consequences of sarcopenia.
Methods: We investigated the utility of SARC-F in the African American Health (AAH) study, Baltimore Longitudinal Study of Aging (BLSA), and National Health and Nutrition Examination Survey (NHANES). Internal consistency reliability for SARC-F was determined using Cronbach's alpha. We evaluated SARC-F factorial validity using principal components analysis and criterion validity by examining its association with exam-based indicators of sarcopenia. Construct validity was examined using cross-sectional and longitudinal differences among those with high (≥4) vs. low (<4) SARC-F scores for mortality and health outcomes.
Results: SARC-F exhibited good internal consistency reliability and factorial, criterion, and construct validity. AAH participants with SARC-F scores ≥ 4 had more Instrumental Activity of Daily Living (IADL) deficits, slower chair stand times, lower grip strength, lower short physical performance battery scores, and a higher likelihood of recent hospitalization and of having a gait speed of <0.8 m/s. SARC-F scores ≥ 4 in AAH also were associated with 6 year IADL deficits, slower chair stand times, lower short physical performance battery scores, having a gait speed of <0.8 m/s, being hospitalized recently, and mortality. SARC-F scores ≥ 4 in the BLSA cohort were associated with having more IADL deficits and lower grip strength (both hands) in cross-sectional comparisons and with IADL deficits, lower grip strength (both hands), and mortality at follow-up. NHANES participants with SARC-F scores ≥ 4 had slower 20 ft walk times, had lower peak force knee extensor strength, and were more likely to have been hospitalized recently in cross-sectional analyses.
Conclusions: The SARC-F proved internally consistent and valid for detecting persons at risk for adverse outcomes from sarcopenia in AAH, BLSA, and NHANES.
Wei W, Mao Z, Chen M, Meng L Front Med (Lausanne). 2025; 12:1500915.
PMID: 40078393 PMC: 11897525. DOI: 10.3389/fmed.2025.1500915.
Muzyka M, Ottaviani S, Caffa I, Bonfiglio T, Parisi E, Guijarro A Cancers (Basel). 2025; 17(5).
PMID: 40075636 PMC: 11898973. DOI: 10.3390/cancers17050789.
Busanello A, Menezes V, Koller O, Volz Andreia A, de Almeida J Trials. 2025; 26(1):78.
PMID: 40050966 PMC: 11884081. DOI: 10.1186/s13063-025-08720-1.
A wearable approach for Sarcopenia diagnosis using stimulated muscle contraction signal.
Shin J, Song K, Kim S, Choi S, Lee H, Kim I Biomed Eng Lett. 2025; 15(2):443-454.
PMID: 40026882 PMC: 11871215. DOI: 10.1007/s13534-025-00461-z.
Zhuang M, Gu Y, Wang Z, He X, Chen N Sci Rep. 2025; 15(1):6981.
PMID: 40011687 PMC: 11865505. DOI: 10.1038/s41598-025-91644-2.